Effectiveness of switching from protease inhibitors to dolutegravir in combination with nucleoside reverse transcriptase inhibitors as maintenance antiretroviral therapy among HIV-positive patients.
PMID: 30905695
2019
International journal of antimicrobial agents
Abstract: The presence of M184V/I mutation and other NRTI resistance-associated mutations (RAMs) did not increase the risk of virological failure in either group.
Incidence and types of HIV-1 drug resistance mutation among patients failing first-line antiretroviral therapy.
PMID: 30928089
2019
Journal of pharmacological sciences
Abstract: RESULTS: 103 cases were successfully amplified, and the main drug resistance mutations in the reverse transcriptase (RT) region were M184V (50.49%), K103N (28.16%), Y181C (25.24%), and K65R (27.18%), while no drug main resistance mutation was found in the protease (PR) region.
The rate of mother-to-child transmission of antiretroviral drug-resistant HIV strains is low in the Swiss Mother and Child HIV Cohort Study.
Abstract: HIV-sDRM (M184V 23%; K103N 4.5%; D67N 13.6%) occurred in 16/22 (73%) after 4 years, half of whom were treatment naïve.
Abstract: Using stored plasma (n = 66) and mononuclear cell (n = 43) samples from the children, HIV-tDRM (M184V) was identified in 1 of 22 (4.5%) mothers (1/11 treated, 9%) and was followed by HIV-sDRM at 10 months of age.
Diversity of HIV-1 genotypes and high prevalence of pretreatment drug resistance in newly diagnosed HIV-infected patients in Shanghai, China.
Discussion: This scenario differs from that of other PrEP drugs such as FTC, which can rapidly select for the M184V/I mutation within days or weeks.
HIV Drug Resistance Mutations in Patients with HIV and HIV-TB Coinfection After Failure of First-Line Therapy: A Prevalence Study in a Resource-Limited Setting.
PMID: 31117863
2019
Journal of the International Association of Providers of AIDS Care
Abstract: M184V, M41L, D67N, G190A, A98G, and K103N were the most common mutations seen.
Table:
Discussion: M184V was the most commonly observed NRTI-associated mutation in both groups (64% in HIV-TB patients and 76% in HIV-positive patients).
Discussion: The high prevalence of thymidine analog mutations in the patients included in this study might explain the increased DRMs in HIV and HIV-TB patients despite the known protective role of the M184V mutation.
Discussion: This patient had 3 thymidine analog mutations, and the M184V mutation, which makes it resistant to all NRTIs.
Trends in HIV-1 Drug Resistance Mutations from a U.S. Reference Laboratory from 2006 to 2017.
PMID: 31169022
2019
AIDS research and human retroviruses
Abstract: M184V/I decreased from 48.3% to 29.4%.
Antiretroviral drug resistance mutations among patients failing first-line treatment in Hanoi, Vietnam.
Abstract: In genetic mutations to NRTIs, M184V mutation was 88.4%.
Discussion: In a previous pre-treatment HIV-DR study, NNRTI resistance was K103N, Y181C, Y188C and G190A, and NRTI resistance was V75M and M184V.
Discussion: Patients receiving incomplete suppressive 3TC regimens usually develop M184V as their first mutation.
Discussion: Regarding, 88.4% of patients had HIV-DR in first-line ART failures was the M184V mutation.
Discussion: This finding can be explained by the M184V mutation in line with la
Lamivudine-based maintenance antiretroviral therapies in patients living with HIV-1 with suppressed HIV RNA: derivation of a predictive score for virological failure.
Abstract: A score of 2 was assigned to non-B viral subtype, 3 to residual viraemia >= 20 copies/mL, >= 10 previous therapeutic lines and African ethnicity, 4 to baseline CD4 count < 200 cells/muL, and 7 to the presence of at least one RAM (excluding M184V).
Abstract: RESULTS: During a median 2 years of follow-up time, 35 VFs occurred; predictors of VF were baseline residual HIV RNA between 20 and 36 copies/mL, African ethnicity, >= 10 therapeutic lines, the presence of at least one resistance-associated mutation (RAM) for resistance to current drugs (excluding M184V), a non-B viral subtype and a baseline CD4 count < 200 cells/muL.
HIV mutation literature information.
PMID: 
2019
International journal of antimicrobial agents
Browser Board
Co-occurred Entities
Filtrator
ViMRT